Across GLP-1 trials, about 60% of lost weight returns within a year and about 75% over the longer regain curve. Continued treatment has stronger evidence than complete withdrawal
Addressing Nutrition Gaps During GLP-1/GIP Therapy Experts have increasingly highlighted the importance of addressing nutritional deficiencies and muscle health challenges associated with GLP-1/GIP therapies
Abstract We conducted a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database (2005 Q22024 Q3) to evaluate neurological adverse events (NAEs) associated with six glucagon-like peptide-1 receptor agonists (GLP-1 RAs): exenatide, liraglutide, lixisenatide, dulaglutide, semaglutide, and tirzepatide
Incorporating Blueberry Fruit into your diet helps enhance brain health, support heart health, and provide essential nutrients for overall vitality
Kircik LH, Alonso-Llamazares J, Bhatia N, et al